Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis

Parasitology Research

Volumn 105, Issue 2, 2009, Pages 463-469

  Woerly, Virginie ^a   Maynard, Laurence ^a   Sanquer, Annaële ^a   Eun, Hyone Myong ^a  

^a Virbac SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; DUOWIN; MILTEFORAN; MILTEFOSINE; PERMETHRIN; PYRIPROXYFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL MONITORING; BLOOD SAMPLING; BONE MARROW EXAMINATION; CHRONOTHERAPY; CONTROLLED STUDY; DOG; DOG DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; LEISHMANIASIS; MALE; MIXED INFECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; DOG DISEASES; DOGS; FEMALE; LEISHMANIASIS, VISCERAL; MALE; PHOSPHORYLCHOLINE; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 67649553162     PISSN: 09320113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00436-009-1404-2     Document Type: Article

References (18)

1. V Achterberg G Gercken 1987 Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastigotes Mol Biochem Parasitol 23 117 122
2. V Achterberg G Gercken 1987 Metabolism of ether lysophospholipids in Leishmania donovani promastigotes Mol Biochem Parasitol 26 277 287
3. G Baneth AF Koutinas L Solano-Gallego P Bourdeau L Ferrer 2008 Canine leishmaniosis - new concepts and insights on an expanding zoonosis: part one Trends Parasitol 24 7 324 330
4. J Carrio M Portus 2002 In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate BMC Pharmacol 2 11
5. SL Croft K Seifert M Duchêne 2003 Antiprotozoal activities of phospholipids analogues Mol Biochem Parasitol 126 165 172
6. I Cruz C Cañavate JM Rubio MA Morales C Chicharro F Laguna M Jiménez-Mejías G Sirena S Videla J Alvar 2002 A nested polymerase chain reaction (Ln-PCR) for diagnosing and monitoring Leishmania infantum infection in patients co-infected with human immunodeficiency virus Trans R Soc Trop Med Hyg 96 1 185 189
7. P Denerolle G Bourdoiseau 1999 Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases) J Vet Intern Med 13 5 413 415
8. M Gramiccia L Gradoni S Orsini 1992 Decreased sensitivity to meglumine antimoniate (Glucantime®) of Leishmania infantum isolated from dogs after several courses of drug treatment Ann Trop Med Parasitol 86 6 613 620
9. TK Jha S Sundar CP Thakur P Bachmann J Karbwang C Fischer A Voss J Berman 1999 Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis N Engl J Med 341 24 1795 1800
10. G Miro L Cardoso MG Pennisi G Oliva G Baneth 2008 Canine leishmaniosis - new concepts and insights on an expanding zoonosis: part two Trends Parasitol 24 8 371 377
11. R Molina G Miro R Galvez J Nieto MA Descalzo 2006 Evaluation of a spray of permethrin and pyriproxyfen for the protection of dogs against Phlebotomus perniciosus Vet Rec 159 7 206 209
12. C Noli ST Auxillia 2005 Treatment of canine old world visceral leishmaniasis: a systematic review Vet Dermatol 16 213 232
13. CB Palatnik-de-Sousa 2008 Vaccines for leishmaniasis in the fore coming 25 years Vaccine 26 1709 1724
14. JM Requena S Iborra J Carrion C Alonso M Soto 2004 Recent advances in vaccines for leishmaniasis Expert Opin Biol Ther 4 9 1505 1517
15. M Roze 2005 Canine leishmaniasis. A spreading disease. Diagnosis and treatment Eur J Companion Anim Pract 15 1 39 52
16. H Sindermann J Engel 2006 Development of miltefosine as on oral treatment for leismaniasis Trans R Soc Trop Med Hyg 100S S17 S20
17. S Sundar TK Jha CP Thakur SK Bhattacharya M Rai 2006 Oral miltefosine for the treatment of Indian visceral leishmaniasis Trans R Soc Med Hyg 100 Suppl.1 S26 S33
18. NK Verma CS Dey 2004 Possible mechanism of miltefosine-mediated death of Leishmania donovani Antimicrob Agents Chemother 48 8 3010 3015